Testing how fat in the liver affects statin use in kids
Treatments studied
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This early study tests whether “liver fat” changes how a statin (rosuvastatin) works in children and teens. It may help doctors choose safer or more effective dosing in kids based on biology and a specific genetics marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 8 and 21 years old
- Have high LDL (“bad”) cholesterol above 130 mg/dL
- Have the specific SLCO1B1 genetic type called c.521TT
- Be willing to do an overnight fast of about 8 hours before visits
- Join the Cardiology Pharmacogenomic Repository
- Be able to have MRI scans (no unsafe metal, and you can fit comfortably)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new medicine, lerodalcibep, can safely lower cholesterol in children ages 6 to 17 who have a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It aims to help children whose cholesterol stays high despite taking standard cholesterol-lowering drugs.
This study looks at how your genes affect the way your body responds to rosuvastatin, a drug that lowers cholesterol. It aims to find the best dose for you based on your genetic makeup.
This study tests whether the drug rosuvastatin, a cholesterol-lowering medicine, can improve liver health in people with cirrhosis. If you have compensated cirrhosis (no recent serious liver problems), you might be able to join.
This is a research study testing whether specific gene changes are linked to fatty liver and a cholesterol pattern that raises heart risk. It may help researchers understand who is most likely to develop these conditions and why, which could guide future prevention.
This study looks at whether the cholesterol-lowering drug rosuvastatin affects how your body adapts to running training, and if it's safe to take while training. You would take rosuvastatin (or continue taking it) while keeping up your usual running routine, and we would monitor your fitness and safety over 3 months.
This early study looks at how a statin (cholesterol-lowering medicine) affects people with primary sclerosing cholangitis (PSC) by measuring changes using multiple types of health data. It may help researchers understand which people benefit and how PSC biology changes with treatment.
Hear when a new Cholesterol; Lipidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.